医学
去神经支配
肾交感神经失神经
血压
指南
肾动脉
重症监护医学
高血压的病理生理学
心脏病学
交感神经系统
干预(咨询)
内科学
风险因素
抵抗性高血压
肾
病理
护理部
作者
Kenneth Guber,Ajay J. Kirtane
标识
DOI:10.1016/j.ekir.2022.06.019
摘要
Arterial hypertension is the most prevalent global modifiable risk factor for cardiovascular morbidity and mortality. Despite the availability of numerous pharmacologic treatments, many patients do not achieve guideline-recommended blood pressure targets. Therefore, renal sympathetic denervation (RDN), a process in which catheter-directed techniques are used to ablate portions of the renal artery to reduce sympathetic activity, has been extensively investigated as a complementary and nonpharmacologic approach for the treatment of arterial hypertension. This review seeks to discuss the pathophysiological rationale of this strategy, to survey its history and development, and to highlight the current clinical evidence and possible future directions of its employment. In sum, RDN has demonstrated itself to be a safe and well-tolerated endovascular intervention that can reliably contribute to improved blood pressure control and, perhaps ultimately, significant cardiovascular prognosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI